{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:59:54Z","timestamp":1771023594829,"version":"3.50.1"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Mammary adenocarcinoma, the most common cancer in female dogs, often exhibits the lymph node and lung metastases and has a higher mortality rate. However, mammary adenocarcinoma has no established treatment, except early surgical excision. Canine mammary carcinoma has many common features with human mammary carcinoma, including clinical characteristics, heterogeneity, and genetic aberrations, making it an excellent spontaneous tumor model for human breast cancer. Diverse cancers comprised heterogeneous cell populations originating from cancer stem cells (CSCs) with self-renewal ability. Therefore, in addition to conventional therapy, therapeutic strategies targeting CSCs are essential for cancer eradication. The present study aimed to extract inhibitors of canine mammary CSCs that suppress their self-renewal ability. Sphere-formation assay, which evaluates self-renewal ability, was performed for the canine mammary cancer cell lines CTBp and CNMp. The spheres formed in this assay were used in inhibitor library screening, which identified various signaling pathways such as proteosome, stress inducer, and mammalian target of rapamycin (mTOR). The present study focused on the mTOR signaling pathway. Western blotting showed higher levels of phosphorylated mTOR in sphere-forming CTBp and CNMp cells than in adherent cells. Drug sensitivity examination using the mTOR inhibitors everolimus and temsirolimus revealed dose-dependent reductions in viability among both sphere-forming cells and adherent cells. Expression of phosphorylated mTOR in adherent and sphere-forming cells decreased by everolimus and temsirolimus treatment. In mice transplanted with CTBp-derived spheres, everolimus treatment significantly decreased tumor volume compared to control. These results reveal that the mTOR signaling pathway may be a potential to be a therapeutic target in both cancer cells and CSCs. Novel therapeutic strategies for canine mammary carcinoma are expected to benefit to human breast carcinoma as well.<\/jats:p>","DOI":"10.3389\/fonc.2023.1100602","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:21:17Z","timestamp":1675279277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["mTOR pathway as a potential therapeutic target for cancer stem cells in canine mammary carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Masaki","family":"Michishita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Nakahira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daigo","family":"Azakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukino","family":"Machida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"B1","volume-title":"Histological classification of mammary tumors of the dog and the cat","author":"Misdorp","year":"1999"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17225","article-title":"Characterization of potential driver mutations involved in human breast cancer by computational approaches","volume":"8","author":"Rajendran","year":"2017","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8411","article-title":"Canine mammary tumors as a model for human disease","volume":"15","author":"Abdelmegeed","year":"2018","journal-title":"Oncol Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11122006","article-title":"Somatic mutation of PIK3CA (H1047R) is a common driver mutation hotspot in canine mammary tumors as well as human breast cancers","volume":"11","author":"Lee","year":"2019","journal-title":"Cancers (Basel)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.623800","article-title":"From conventional to precision therapy in canine mammary cancer: A comprehensive review","volume":"8","author":"Valdivia","year":"2021","journal-title":"Front Vet Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/s41467-020-16936-9","article-title":"NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation","volume":"11","author":"Miao","year":"2020","journal-title":"Nat Commun"},{"key":"B7","article-title":"Factors influencing canine mammary cancer development and postsurgical survival","volume":"43","author":"Schneider","year":"1969","journal-title":"J Natl Cancer Inst"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1892\/0891-6640(2004)18<219:eatopt>2.0.co;2","article-title":"Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors","volume":"18","author":"Poirier","year":"2004","journal-title":"J Vet Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1892\/0891-6640(2006)20[1184:patimm]2.0.co;2","article-title":"Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel","volume":"20","author":"Simon","year":"2006","journal-title":"Vet Intern Med"},{"key":"B10","article-title":"Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors","volume":"26","author":"Lavalle","year":"2012","journal-title":"In Vivo."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.9775\/kvfd.2020.24112","article-title":"Efficacy and toxicity of doxorubicin and cyclophosphamide for the neoadjuvant treatment of locally advanced stage canine mammary tumors","volume":"26","author":"Kuruoglu","year":"2020","journal-title":"Kafkas Univ Vet Fak Derg."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12760","article-title":"Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate","volume":"20","author":"Alonso-Miguel","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0147-52-67","article-title":"Evaluation of adverse effects in tamoxifen exposed healthy female dogs","volume":"52","author":"Tavares","year":"2010","journal-title":"Acta Vet Scand"},{"key":"B14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12032-022-01749-1","article-title":"Molecular perspective on targeted therapy in breast cancer: a review of current status","volume":"39","author":"Demir Cetinkaya","year":"2022","journal-title":"Med Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells\u2013perspectives on current status and future directions: AACR workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2499","article-title":"Cancer stem cells in solid tumours: accumulating evidence and unresolved questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat Rev Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000123845","article-title":"Cancer stem cells in breast: current opinion and future challenges","volume":"75","author":"Charafe-Jauffret","year":"2008","journal-title":"Pathobiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2020.105560","article-title":"Understanding of tumourigenesis in canine mammary tumours based on cancer stem cell research","volume":"265","author":"Michishita","year":"2020","journal-title":"Vet J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.tvjl.2007.07.025","article-title":"Isolation and characterisation of cancer stem cells from canine osteosarcoma","volume":"175","author":"Wilson","year":"2008","journal-title":"Vet J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2010.11.016","article-title":"Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines","volume":"91","author":"Michishita","year":"2011","journal-title":"Res Vet Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810396106","article-title":"Identification of cancer stem cells derived from a canine lung adenocarcinoma cell line","volume":"48","author":"Nemoto","year":"2011","journal-title":"Vet Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3021744","article-title":"Canine mammary cancer stem cells are radio- and chemo- resistant and exhibit an epithelial-mesenchymal transition phenotype","volume":"3","author":"Pang","year":"2011","journal-title":"Cancers (Basel)."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2012.01.006","article-title":"Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines","volume":"193","author":"Michishita","year":"2012","journal-title":"Vet J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2014.07.006","article-title":"Comparison of cancer stem cell antigen expression by tumor cell lines and by tumor biopsies from dogs with melanoma and osteosarcoma","volume":"161","author":"Guth","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2014.01.004","article-title":"Identification of tumor-initiating cells in a canine hepatocellular carcinoma cell line","volume":"96","author":"Michishita","year":"2014","journal-title":"Res Vet Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.16-0412","article-title":"Identification of tumor-initiating cells derived from two canine rhabdomyosarcoma cell lines","volume":"79","author":"Kishimoto","year":"2017","journal-title":"J Vet Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1111\/vco.12110","article-title":"Radioresistance of cancer stem-like cell derived from canine tumours","volume":"14","author":"Tanabe","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-014-0184-9","article-title":"The long-acting COX-2 inhibitor mavacoxib (Trocoxil\u2122) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro","volume":"10","author":"Pang","year":"2014","journal-title":"BMC Vet Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2012.02.008","article-title":"Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential","volume":"318","author":"Barbieri","year":"2012","journal-title":"Exp Cell Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12935-017-0392-z","article-title":"Screening of breast cancer stem cell inhibitors using a protein kinase inhibitor library","volume":"17","author":"Choi","year":"2017","journal-title":"Cancer Cell Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111748","article-title":"A high-throughput screen identifies inhibitors of lung cancer stem cells","volume":"140","author":"She","year":"2021","journal-title":"BioMed Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2006.00098.x","article-title":"Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their e-cadherin expression","volume":"4","author":"Uyama","year":"2006","journal-title":"Vet Comp Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.12268sc","article-title":"Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma","volume":"121","author":"Michishita","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3747\/co.22.2393","article-title":"Novel agents and associated toxicities of inhibitors of the pi3k\/Akt\/mtor pathway for the treatment of breast cancer","volume":"22","author":"Chia","year":"2015","journal-title":"Curr Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B38","article-title":"PI3K\/Akt\/mTOR signaling pathway in cancer stem cells: from basic research to clinical application","volume":"5","author":"Xia","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810956106","article-title":"The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations","volume":"106","author":"Dubrovska","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12493","article-title":"PI3K\/Akt\/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells","volume":"42","author":"Chen","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26088","article-title":"The Akt\/mTOR pathway in cancer stem\/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma","volume":"9","author":"Bahmad","year":"2018","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41419-021-03391-7","article-title":"Survival of salivary gland cancer stem cells requires mTOR signaling","volume":"12","author":"Andrade","year":"2021","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4418","article-title":"Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0383-6","article-title":"Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo","volume":"33","author":"Zhu","year":"2012","journal-title":"Tumour Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1170-8","article-title":"Everolimus in combination with letrozole inhibit human breast cancer MCF-7\/Aro stem cells via PI3K\/mTOR pathway: an experimental study","volume":"35","author":"Liu","year":"2014","journal-title":"Tumour Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/srep00362","article-title":"Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells","volume":"2","author":"Song","year":"2012","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087979","article-title":"Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined","volume":"9","author":"Lee","year":"2014","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2012.05.002","article-title":"Immunohistochemical analysis of the Akt\/mTOR\/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas","volume":"147","author":"Murai","year":"2012","journal-title":"J Comp Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2014.12.004","article-title":"Activation of mammalian target of rapamycin in canine mammary carcinomas: an immunohistochemical study","volume":"152","author":"Delgado","year":"2015","journal-title":"J Comp Pathol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.rvsc.2018.11.006","article-title":"P-mTOR, p-4EBP-1 and eIF4E expression in canine prostatic carcinoma","volume":"122","author":"Rivera-Calder\u00f3n","year":"2019","journal-title":"Res Vet Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2018.12.024","article-title":"Immunohistochemical expression of selected phosphoproteins of the mTOR signalling pathway in canine cutaneous squamous cell carcinoma","volume":"245","author":"Sanz Ressel","year":"2019","journal-title":"Vet J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2021.02.001","article-title":"Histological and immunohistochemical evaluation of phosphorylated mechanistic target of rapamycin in canine skin tumours","volume":"184","author":"Mathew","year":"2021","journal-title":"J Comp Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.69.8.1079","article-title":"Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs","volume":"69","author":"Gordon","year":"2008","journal-title":"Am J Vet Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.70.2.263","article-title":"Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines","volume":"70","author":"Kent","year":"2009","journal-title":"Am J Vet Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-8-73","article-title":"The class I PI3K\/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention","volume":"8","author":"Chen","year":"2012","journal-title":"BMC Vet Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200634","article-title":"In vitro effects of PI3K\/mTOR inhibition in canine hemangiosarcoma","volume":"13","author":"Pyuen","year":"2018","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12885-015-1235-8","article-title":"In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors","volume":"15","author":"Barbieri","year":"2015","journal-title":"BMC Cancer."},{"key":"B60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tvjl.2015.04.026","article-title":"Anti-tumour effect of metformin in canine mammary gland tumour cells","volume":"205","author":"Saeki","year":"2015","journal-title":"Vet J"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12512","article-title":"Synergistic targeted inhibition of MEK and dual PI3K\/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma","volume":"29","author":"Wei","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2846","article-title":"Targeting hedgehog\u2013a cancer stem cell pathway","volume":"16","author":"Merchant","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cancers7030851","article-title":"Hedgehog signaling in the maintenance of cancer stem cells","volume":"7","author":"Cochrane","year":"2015","journal-title":"Cancers (Basel)."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0054","article-title":"Hedgehog signaling and bmi-1 regulate self-renewal of normal and malignant human mammary stem cells","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"B65","article-title":"The hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-\/low subpopulation and the side population of breast cancer cells","volume":"29","author":"Tanaka","year":"2009","journal-title":"Anticancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081126","article-title":"The hedgehog signaling pathway: A viable target in breast cancer","volume":"11","author":"Bhateja","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12149","article-title":"Hedgehog signaling is activated in canine transitional cell carcinoma and contributes to cell proliferation and survival","volume":"15","author":"Gustafson","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231762","article-title":"Evaluation of canonical hedgehog signaling pathway inhibition in canine osteosarcoma","volume":"15","author":"Baldanza","year":"2020","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12828","article-title":"Expression of the hedgehog signalling pathway and the effect of inhibition at the level of smoothened in canine osteosarcoma cell lines","volume":"20","author":"Nam","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of proteasome inhibition for extending remissions (APEX) investigators. bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B72","article-title":"Velcade (Bortezomib) receives 2 new FDA indications: For retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj131","article-title":"Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits","volume":"17","author":"Yang","year":"2006","journal-title":"Ann Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001677","article-title":"Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events","volume":"3","author":"Mei\u00dfner","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"B75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jconrel.2014.12.043","article-title":"Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy","volume":"208","author":"Shen","year":"2015","journal-title":"J Control Release."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4666","article-title":"Resistance of papillary thyroid cancer stem cells to chemotherapy","volume":"12","author":"Giuffrida","year":"2016","journal-title":"Oncol Lett"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21341","article-title":"Development of a brain metastatic canine prostate cancer cell line","volume":"71","author":"Thudi","year":"2011","journal-title":"Prostate"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.12-0168","article-title":"Analyses on activation of NF-\u03baB and effect of bortezomib in canine neoplastic lymphoid cell lines","volume":"75","author":"Kojima","year":"2013","journal-title":"J Vet Med Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2013.08.003","article-title":"The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo","volume":"198","author":"Ito","year":"2013","journal-title":"Vet J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12413","article-title":"Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma","volume":"16","author":"Patatsos","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2334-2337","article-title":"Breast cancer stem cell: the roles and therapeutic implications","volume":"74","author":"Yang","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-017-0595-x","article-title":"Cancer stem cell niche models and contribution by mesenchymal stroma\/stem cells","volume":"16","author":"Melzer","year":"2017","journal-title":"Mol Cancer."},{"key":"B84","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.7150\/thno.62676","article-title":"Tumor microenvironment-based screening repurposes drugs targeting cancer stem cells and cancer-associated fibroblasts","volume":"11","author":"Lee","year":"2021","journal-title":"Theranostics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1100602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:21:24Z","timestamp":1675279284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1100602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":85,"alternative-id":["10.3389\/fonc.2023.1100602"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1100602","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"article-number":"1100602"}}